Identification of Inflammatory Cell Death‐Related Prognostic Signature and Its Regulatory Mechanism in Lung Adenocarcinoma Authors: Yalun Yang, Di Liu, Shengwei Ma Published: 2026 ABSTRACT ABSTRACTObjectiveThis study investigated how inflammatory cell death‐associated regulators influence the prognosis of lung adenocarcinoma (LUAD) and elucidated their underlying mechanisms.MethodsLUAD RNA‐seq data from UCSC‐Xena (training) and GSE72094 (validation) were analyzed. Inflammatory cell death regulators were identified, and LUAD subtypes were classified based on their expression. Subtypes were compared with respect to prognosis, clinical features, immune microenvironment, HLA genes, and immune checkpoints. Prognosis‐related regulators and independent factors were identified, and a RiskScore model was built. Genomic alterations, drug sensitivity, immunotherapy response, and metabolic differences were analyzed across risk‐stratified cohorts. Knockdown of TFDP1 in A549 cells was performed in vitro, and its effects on cell function were evaluated via RT‐qPCR, Western blot, CCK‐8, Transwell, and flow cytometry.ResultsThe research revealed 15 upregulated and 9 downregulated genes associated with inflammatory cell death, which were employed to stratify LUAD cases into two subtypes (Cluster 2 exhibited longer overall survival and higher immune/stromal scores). The seven‐gene prognostic model (comprising BAK1, BMF, CYCS, FADD, IL1A, TFDP1, and YWHAG) demonstrated robust predictive power for LUAD patient survival risk. Notably, the high‐risk cohort exhibited higher TIDE scores and lower IPS scores than the low‐risk group. IL1A was positively correlated with 11 immune cell types and negatively correlated with 4. Drugs such as docetaxel and parthenolide may target this model. The study identified significant differences in 14 metabolic pathway enrichments between risk groups, particularly in fatty acid and fructose metabolism. Experimental validation confirmed TFDP1 upregulation in LUAD, and its knockdown suppressed A549 cell proliferation, migration, and invasion while inducing apoptosis.ConclusionA seven‐gene inflammatory cell death‐based signature for LUAD was developed, highlighting its role in immune regulation and its potential for immunotherapy. Experimental validation identified TFDP1 as a key regulator of inflammatory cell death processes in LUAD progression. Abbreviations cytolytic activity score immunophenoscore lung adenocarcinoma non‐small‐cell lung cancer overall survival programmed cell death protein–protein interaction tumor immune dysfunction and exclusion Introduction Global cancer statistics indicate that lung cancer has become the leading cause of cancer‐associated mortality in China, with approximately 870,000 newly diagnosed cases recorded in 2022 [1]. The majority (85%) of lung cancer cases are classified as non‐small cell lung cancer (NSCLC), among which lung adenocarcinoma (LUAD) represents the predominant histological subtype [2]. Combination chemotherapy, radiation, and surgery are conventional therapies for LUAD. Nevertheless, the disease is frequently diagnosed at advanced stages, underscoring the urgent need for improved diagnostic and prognostic tools for early‐stage LUAD. Inflammatory cell death represents a category of interconnected programmed cell death (PCD) modalities consisting of pyroptosis, apoptosis, and necroptosis, all of which trigger inflammatory signaling cascades within the tumor microenvironment. It is well known that PCD is a hallmark of cancer occurrence, development, and prognosis. Regulators governing inflammatory cell death have been widely reported to participate in infectious disorders and autoimmune diseases [3]. The improvement of biological information databases provides a foundation for investigating tumor treatment‐ and prognosis‐associated biomarkers by integrating the transcriptome and proteome [4]. For instance, previous pan‐cancer studies demonstrated that elevated expression of PANoptosis‐related genes predicts favorable overall survival (OS) in cutaneous melanoma, whereas it correlates with poor prognosis in low‐grade glioma and renal clear cell carcinoma [5]. Wang et al. demonstrated that FADD is a novel PANoptosis‐related gene associated with LUAD prognosis and a valuable biomarker [6]. Prior studies have separately investigated single types of programmed cell death in LUAD, yet an integrated systematic analysis of combined inflammatory cell death regulators (covering pyroptosis, apoptosis, necroptosis) for prognostic stratification, immune microenvironment remodeling, and therapeutic sensitivity prediction is still absent. Thus, to explore the regulatory role of inflammatory cell death regulators in LUAD prognosis and potential mechanisms, RNA sequencing data from the UCSC‐Xena platform served as the training cohort, and GSE72094 from NCBI GEO was used as the validation cohort to investigate differentially expressed (DE) inflammatory cell death regulators in LUAD. Finally, a novel prognostic signature for LUAD based on inflammatory cell death‐related genes was constructed. Targeted drugs and related immune microenvironments have led to the development of new immunotherapies for LUAD. Materials and Methods Preprocessing of Microarray Data The transcriptomic data and clinical survival outcomes of LUAD patients were sourced from the UCSC‐Xena platform [7] as the training dataset. In total, 568 samples, including 58 paracancerous and 510 cancerous tissues, were enrolled. The prognostic information of 497 cancer tissues was obtained from the cBioPortal database, including age, gender, TNM stage, tumor stage, Prior Cancer Diagnosis Occurrence, location of lung parenchyma, primary tumor site, tobacco smoking history, adjusted postoperative targeted therapy, primary therapy output success type, altered fraction genome, and tumor mutation burden (TMB). The GSE72094 database was obtained from NCBI GEO database [8] and designed as the validation dataset. The final dataset comprised 398 tissue specimens with corresponding survival data. The probe expression matrix and annotation file were downloaded after pretreatment, standardization, and log2 conversion. Unmapped probes were eliminated via one‐to‐one correspondence between probe identifiers and gene symbols. When multiple probes corresponded to the same gene, their average expression was computed as the representative value. Screening and Network Analysis of Differentially Expressed Inflammatory Cell Death‐Related Genes in TCGA‐LUAD We integrated three core inflammatory cell death subroutines (pyroptosis, apoptosis, necroptosis) and collected their corresponding regulatory genes from published literature [9], including 26 pyroptosis‐, 32 apoptosis‐, and 8 necroptosis‐related genes, collectively defined as inflammatory cell death‐related genes in this study. Using the TCGA LUAD expression matrix, we obtained inflammatory cell death gene expression levels per sample. The limma R package with empirical Bayesian moderation was applied to identify DE genes between LUAD tumor and paracancerous tissues [10]. Adj.p < 0.05 and |logFC| > 0.5 were set as the thresholds for selecting DE inflammatory cell death genes. The Pearson correlation coefficient and a significant p‐value between LUAD and normal controls were calculated based on differential expression of inflammatory cell death genes, and a correlation heat map was generated. We utilized STRING (v10.0) [11] to build a PPI network, enabling the investigation of interactions among differentially expressed inflammatory cell death‐related genes. Genes with PPI scores > 0.4 were selected for network construction. Identification and Clinical Characterization of Inflammatory Cell Death‐Associated Molecular Subtypes Using the CONSENSusClusterPlus package in R3.6.1 (v1.54.0) [12], we stratified samples into subgroups according to inflammatory cell death gene expression differences. The analysis was configured using the PAM clustering algorithm and Spearman correlation, with item and feature subsampling proportions set at 0.8 and 0.9, respectively. Using the expression profiles of all LUAD genes from TCGA, we computed the scorch death score, apoptosis score, programmed death score, and extensive apoptosis score for each sample. These scores were derived by applying the ssGSEA algorithm (implemented in the R package GSVA, version 1.36.2) [13] using 26 pyroptosis‐related genes, 32 apoptosis‐related genes, and 8 necroptosis‐related genes as the enrichment background. The Wilcoxon test was used to assess differences in these cell scores across subtypes, followed by visualization with a violin plot. The prognosis data of the samples were utilized to generate Kaplan–Meier (KM) survival curves for the two distinct subtypes. We conducted a comparative analysis of the clinical features among the subtypes. For categorical data, the chi‐squared test was utilized; for continuous data, the Wilcoxon test was applied. Furthermore, we applied the same unsupervised clustering approach to an external independent dataset (GSE72094) to assess the stability and reproducibility of the molecular subtypes. Integrated Immunological and Functional Characterization of the Identified Molecular Subtypes To further characterize the immune microenvironmental differences between subtypes, we employed CIBERSORT (http://cibersort.stanford.edu/index.php) [14, 15] to estimate the abundance of 22 immune cell types. We employed the R package MCPcounter to quantify infiltration levels of eight immune and two stromal cell types in LUAD samples using gene expression data [16]. To evaluate the tumor microenvironment, the ESTIMATE [17] algorithm was used to derive matrix, immune, and microenvironment scores for all samples. Subsequently, the Wilcoxon rank‐sum test was applied to assess the significance of score variations across the identified subtypes. Boxplots were created to visually depict the comparative expression levels of immune checkpoint genes and HLA family members among the subtypes, with statistical significance determined by the T‐test. To identify hallmark gene sets with significant enrichment in specific subtypes, we performed GSEA with the clusterProfiler package (ver. 3.8.1) [18]. The “h.all.v7.4.symbols” collection from MSigDB v7.1 [19] served as the reference gene set. Construction and Verification of the Inflammatory Cell Death‐Related Prognostic Signature Univariable Cox regression was employed to screen inflammatory cell death genes for their association with OS, based on clinical follow‐up and gene expression data. The analysis was performed in R (v3.6.1) with the survival package (v2.41‐1) [20], applying a significance threshold of p < 0.05. We utilized 20‐fold cross‐validation combined with LASSO Cox regression to screen optimal prognostic gene combinations from the full set of inflammatory cell death regulators in the glmnet package in R3.6.1 (v2.0‐18) [21] based on expression values and survival and prognosis information from TCGA‐LUAD. According to the gene regression prognosis coefficients derived from integrating extensive apoptosis genes with their expression levels in TCGA‐LUAD specimens, we developed a risk score model. We formulated the corresponding risk score calculation formula as follows: RiskScore=∑βgene×Expgene where β Gene is the LASSO regression coefficient. We validated the model's accuracy by calculating patient risk scores within the GSE72094. The cohort was then dichotomized at the median risk value into high‐ and low‐risk cohorts. KM curves were constructed to investigate the correlation between risk grouping and actual survival prognosis using the survival package v2.41‐1 and the KM curve method in R3.6.1. Simultaneously, the ROC curves of the training and validation sets based on RiskScore for 1‐, 3‐, and 5‐year survival time are shown. A box diagram of the RiskScore distribution was also drawn. To further evaluate the external applicability of the model, in addition to the GSE72094 cohort, this study additionally incorporated the GSE31210 cohort (n = 226) from NCBI GEO as the second independent validation set. Consistently, all samples were stratified into high‐ and low‐risk groups according to the median risk score derived from the training cohort. Kaplan–Meier survival analysis and time‐dependent ROC curve analysis were subsequently performed to verify the robustness of the risk model. Evaluation of Independent Prognostic Factors and Subtype‐Based Risk Stratification To evaluate the role of the RiskScore model as an independent prognostic factor, univariable Cox regression analysis was performed incorporating both the RiskScore and clinicopathological parameters. When the p‐value was < 0.05, the factor was enrolled for multivariate Cox regression analysis. Nomograms were used as independent prognostic clinical factors. Simultaneously, to validate the nomogram's accuracy, we generated both calibration and ROC curves. Genomic Changes in High‐ and Low‐Risk Groups To investigate the gene mutation disparities between high‐ and low‐risk cohorts, we employed the oncoplot function from the R package maftools (version 1.6.15) [22] to visualize the mutation waterfall. This analysis focused on the top 20 genes by mutation frequency within the risk groups. The somatic mutation data were sourced from the TCGA‐LUAD dataset [23], having undergone processing by the Mutect software before download. Drug Sensitivity Analysis and Correlation Between Prognosis Model Gene and Immunity The association between the RiskScore gene and immune cell infiltration was assessed using Spearman correlation analysis, with p‐values used to determine significance, and the results were subsequently visualized in a correlational heatmap. The ridge regression algorithm was applied to transcriptomic data from both GDSC and TCGA to estimate drug sensitivity, quantified by IC50. Using the pRRophetic package (v0.5, https://osf.io/dwzce/?action=download) [24], IC50 values were computed for a set of 138 therapeutic agents. Furthermore, the difference in IC50 values between the high‐ and low‐risk cohorts was compared using the Wilcoxon test. Immunotherapy Response and Metabolic Enrichment To evaluate potential immune checkpoint blockade responses, TIDE scores were derived for all samples in the low‐ and high‐risk cohorts using the TIDE algorithm [25]. This method predicts efficacy by modeling two fundamental tumor immune resistance pathways. A comparative analysis of the resulting scores was then conducted via the Wilcoxon test to assess statistical significance. Following the CYT scoring methodology outlined in previous literature [26], the scores for each sample across the high‐ and low‐risk categories were determined and subjected to a Wilcoxon test‐based comparison. Drawing upon the established immunophenoscore (IPS) scoring framework documented in prior research [27], we quantified the IPS values for patient samples across the high‐risk and low‐risk cohorts. We conducted a statistical comparison using the Wilcoxon test. Metabolic pathways were obtained from c2.cp.kegg.v7.4 symbol gene set of the MSigDB v7.1 database as the enrichment background. The R package GSVA (v1.36.2) was used to calculate the enrichment score of each metabolic pathway in every sample, while the R package limma facilitated the comparison. The threshold for significance was set at an adjusted p‐value < 0.05 and an absolute t‐score > 6. We analyzed the distribution of subtype samples across the stratified high‐ and low‐risk cohorts and presented the results as a bar chart. Cell Culture and Processing A549, H1299, and PC‐9 human LUAD cell lines, together with BEAS‐2B normal human bronchial epithelial cells, were sourced from the ATCC. RPMI‐1640 medium (GIBCO, USA) with 10% FBS (Gibco) was used to culture the cells at 37°C in a 5% CO2 incubator. Lipofectamine 3000 (Invitrogen) was used to transfect cells according to the manufacturer's protocol. The experiment comprised two groups: the control group was transfected with negative control siRNA (si‐NC), while the experimental group was transfected with siRNA targeting TFDP1 (si‐TFDP1). Cells were collected 48 h post‐transfection for subsequent experiments. All cell lines used in this study were authenticated by short tandem repeaTR profiling and confirmed to be free of cross‐contamination prior to use in experiments. All cell lines were routinely tested and confirmed to be negative for mycoplasma contamination before and during the experiments. In Vitro Functional Assays for TFDP1 For molecular verification of knockdown efficiency, total RNA was extracted from transfected A549 cells using TRIzol reagent, followed by cDNA synthesis with the PrimeScript RT Kit (Takara). Gene expression analysis was conducted on the StepOnePlus Real‐Time PCR System (Thermo Fisher Scientific) using PowerUp SYBR Green Master Mix (Thermo Fisher Scientific). The 2−ΔΔCt method was applied to determine the relative expression levels of target genes, using GAPDH as the internal control. Meanwhile, total cellular protein was isolated with RIPA lysis buffer, and protein concentration was quantified by BCA assay. Equal amounts of protein samples were separated by 10% SDS‐PAGE and transferred to PVDF membranes. After blocking with 5% non‐fat milk, the membrane was incubated overnight at 4°C with anti‐TFDP1 (1:2000, ab186831, Abcam) and anti‐GAPDH (1:5000, Proteintech, 60004‐1‐Ig). After washing, the membrane was incubated with HRP‐conjugated secondary antibody (1:2000, ab6721, Abcam) for 2 h. The signals were developed using ECL chemiluminescence reagent (Millipore) and analyzed for grayscale values using ImageJ software. We further assessed the malignant biological behaviors of A549 cells after TFDP1 silencing. Cell proliferative capacity was measured via the CCK‐8 assay: transfected cells were plated at 5 × 103 cells/well in 96‐well plates. CCK‐8 reagent (Dojindo) was introduced at 0, 24, 48, and 72 h post‐seeding, with a subsequent 2‐h incubation. Optical density at 450 nm was then recorded using a microplate reader (BioTek). Transwell chambers without Matrigel (Corning) were employed for the migration assay, while chambers pre‐coated with Matrigel (BD Biosciences) were used for the invasion assay. We resuspended cells in serum‐free medium and seeded 2 × 104 cells into the upper chamber post‐transfection. A medium formulation containing 10% FBS was introduced into the lower chamber. Following a 24‐h incubation period, the cultured cells underwent fixation using 4% paraformaldehyde and were subsequently stained with 0.1% crystal violet. Cell migration/invasion was quantified by counting the cells in five randomly chosen microscopic fields. Finally, flow cytometry (BD FACSCanto II) was used to analyze apoptosis, employing an Annexin V‐FITC/PI apoptosis detection kit (BD Biosciences). Cells were collected 48 h after transfection, rinsed with PBS, and incubated with Annexin V‐FITC and PI in the dark for 15 min. The proportions of early and late apoptotic cells (Annexin V‐positive cells) were calculated using FlowJo software. Statistical Analysis All statistical analyses were performed using R (version 3.6.1) and GraphPad Prism (version 9.5). Continuous variables were first subjected to data quality assessment and outlier screening, and then log2(X + 1) transformation or Z‐score standardization was applied as required by the analysis. Continuous variables that were normally distributed and had homogeneity of variances were expressed as mean ± standard deviation (SD). Comparisons between two groups were performed using two‐tailed independent‐samples Student's t‐test, while comparisons among multiple groups were conducted using one‐way analysis of variance (ANOVA), followed by Tukey's test for post hoc pairwise comparisons. Data that were not normally distributed were expressed as median (interquartile range, IQR). Between‐group comparisons were performed using the Mann–Whitney U test for two‐group comparisons or the Kruskal–Wallis test for multiple‐group comparisons, followed by Dunn's test for post hoc pairwise comparisons. Categorical variables were expressed as frequencies (percentages) and analyzed using Pearson's chi‐square test or Fisher's exact test, as appropriate. Correlations were assessed using Pearson or Spearman correlation analysis. All statistical tests were two‐sided. Prior to analysis, normality was verified using the Shapiro–Wilk test, and homogeneity of variances was evaluated using Levene's test. When multiple comparisons were involved, the Benjamini–Hochberg method was applied to control the false discovery rate (FDR). Unless otherwise specified, the sample size (n) used for each statistical analysis is indicated in the corresponding figure legends, and all in vitro experiments were independently repeated at least three times. A p value < 0.05 (or FDR < 0.05) was considered statistically significant. Results To ensure the reliability and generalizability of the research findings, two independent LUAD cohorts were enrolled in this study. The first cohort was the TCGA‐LUAD dataset retrieved from the UCSC Xena platform, which comprises large‐scale transcriptome sequencing data, comprehensive clinicopathological characteristics, and long‐term follow‐up records. Owing to its high quality and satisfactory data completeness, this cohort was designated as the training set for differentially expressed gene screening, molecular subtyping, prognostic model construction, and subsequent mechanistic investigations. The second cohort was GSE72094 from the GEO database, containing LUAD gene expression profiles and complete survival information. Given its distinct data source from the training cohort, this dataset served as an external validation cohort to assess the stability and predictive performance of the prognostic model. The two‐stage training‐validation design effectively mitigates the risk of model overfitting and improves the reproducibility of research conclusions as well as their potential for clinical translation. Identification of Differentially Expressed Inflammatory Cell Death‐Related Genes To systematically screen differentially expressed inflammatory cell death regulators between LUAD tumor and para‐tumor tissues at the transcriptome level, we analyzed gene expression profiles from TCGA‐LUAD cohort. In total, 15 upregulated genes (CASP2, YWHAG, CHMP4B, TFDP1, CYCS, FADD, CASP3, AIFM1, HMGB2, BAK1, BMF, CHMP4C, TRAF2, CASP6, and E2F1) and nine downregulated genes (IL1A, CASP1, AKT3, IL1B, UACA, TNFSF10, IRF1, FAS, and TLR3) were identified in LUAD. Volcano and bar charts of lung adenocarcinoma are shown in Figure 1A,B, respectively. A correlation heatmap of 24 DE inflammatory cell death‐related genes is shown in Figure 1C, and we found that E2F1 was upregulated in 12 of these genes. A PPI network was constructed, and we found that CASP1, CASP2, and CASP3 were hub genes in the PPI network (Figure 1D). The divergent expression pattern and tight protein interaction of these inflammatory cell death genes indicate their coordinated dysregulation drives aberrant programmed cell death signaling in LUAD. Differentially expressed (DE) inflammatory cell death regulators and protein–protein interaction (PPI) network (n = 510 LUAD tissues and 58 adjacent normal tissues). (A) Volcanic map of DE inflammatory cell death regulators. Red represents upregulated genes, blue represents downregulated genes, and gray represents genes with insignificant difference, limma package Bayesian moderated t‐test; (B) Bar chart of DE inflammatory cell death regulators vs. control. Data are presented as mean ± SD. Statistical significance was assessed by two‐tailed Student's t‐test ****p < 0.0001; (C) Pearson correlation heat map of DE inflammatory cell death regulators. Red represents positive correlation and blue represents negative correlation. The darker and larger the bubble represents the greater absolute value of the correlation coefficient, and a cross represents non‐significance. Pearson correlation analysis. (D) PPI network. Identification of Two Molecular Subtypes Based on Inflammatory Cell Death‐Related Genes To stratify LUAD patients into molecular subgroups with distinct inflammatory cell death activation statuses and compare their clinical and prognostic phenotypes, we performed unsupervised consensus clustering based on the 24 DE inflammatory cell death regulators. Two stable molecular subtypes were successfully classified (Figure 2A). As illustrated in Figure 2B, Cluster 2 exhibited markedly elevated scores for apoptosis, necroptosis, pyroptosis, and inflammatory cell death compared to Cluster 1. Clinical information between Cluster 1 and Cluster 2 is shown in Table 1, and significant differences were found in characteristics such as age, sex, T stage, tumor stage, tobacco smoking history, primary therapy output success type, altered genome fraction, and TMB (nonsynonymous). Survival analysis using the KM curve demonstrated a marked OS advantage for Cluster 2 samples compared with Cluster 1 (Figure 2C). The heatmap delineates the expression profiles of 24 DE inflammatory cell death‐related genes and the distribution of clinical parameters. Taken together, LUAD patients with higher baseline inflammatory cell death‐related signature score exhibit more favorable clinical features and superior survival outcomes. To evaluate the robustness of the above molecular subtypes across different cohorts, we performed validation in an external independent dataset, GSE72094. In GSE72094, two molecular subtypes were also stably identified (Figure S1A), and the overall survival differences between subtypes, as well as the distribution trends of clinicopathological features, were consistent with those observed in the TCGA training cohort (Figure S1B). These external validation results further confirm that the molecular subtypes defined based on inflammatory cell death‐related regulatory genes exhibit good reproducibility and robustness. Consistency clustering, inflammatory cell death score, and Kaplan–Meier (KM) survival curve (n = 510 LUAD samples). (A) Based on the expression profile of differentially expressed inflammatory cell death regulatory factors, consensus clustering analysis was performed on patients from The Cancer Genome Atlas (TCGA) cohort to identify the optimal molecular subtypes. The left panel displays the consensus matrix generated under the clustering number k = 2, where the color gradient from white to dark blue corresponds to increasing clustering consistency between samples. A more uniform color within the diagonal of the matrix indicates superior clustering stability. The middle panel presents consensus cumulative distribution function (CDF) curves across varying clustering numbers (k = 2–6), which were utilized to evaluate the stability of distinct clustering schemes. The right panel illustrates the delta area analysis of the area under the CDF curves. By comprehensively considering clustering stability and classification performance, the optimal clustering number was determined as k = 2. Accordingly, patients were stratified into two molecular subtypes, namely Cluster 1 and Cluster 2; (B) Comparison of apoptosis, necroptosis, pyroptosis and inflammatory cell death scores between the two molecular subtypes. All scores were calculated via single‐sample gene set enrichment analysis (ssGSEA). Violin plots were applied to visualize the score distribution of each group, in which the central horizontal line represents the median, the box denotes the interquartile range, and the width corresponds to sample density. Intergroup differences were statistically assessed using the Wilcoxon rank‐sum test, with corresponding p values labeled in the figure. Compared with Cluster 1, Cluster 2 exhibited significantly higher necroptosis, pyroptosis and inflammatory cell death scores, while the difference in apoptosis scores was relatively modest. These results suggest distinct activities of programmed cell death across the two molecular subtypes; (C) Kaplan–Meier survival curves based on differentially expressed regulators of inflammatory cell death, together with a heatmap depicting the expression profiles of 24 differentially expressed inflammatory cell death‐related genes and the accompanying distribution of clinical characteristics. In the left panel, the horizontal axis represents follow‐up time (years), and the vertical axis denotes overall survival probability. Curves with distinct colors correspond to Cluster 1 and Cluster 2, respectively, while dashed lines indicate 95% confidence intervals. The number‐at‐risk table beneath the curves displays the number of patients remaining under follow‐up at each time point. Intergroup survival differences were compared using the two‐sided Log‐rank test, with corresponding p values presented in the figure. Kaplan–Meier survival analysis revealed a significant overall survival discrepancy between patients of the two molecular subtypes, indicating that the molecular classification constructed based on panoptosis regulatory factors possesses robust capacity for prognostic stratification. In the right panel, each column corresponds to an individual patient, and each row represents a panoptosis‐related gene. The color gradient of the heatmap shifts from blue to red, indicating normalized gene expression levels ranging from low to high. The top annotation bars sequentially display patient cluster subtypes and clinicopathological characteristics, including age, gender, T stage, N stage, M stage, AJCC stage, pathological grade, treatment modality, and survival status. The results demonstrate that the two molecular subtypes exhibit markedly distinct expression patterns of panoptosis regulatory factors, accompanied by divergent clinicopathological features and survival outcomes. These findings further validate the biological and clinical significance of this molecular classification system. TABLE 1Comparison of clinical information among subtypes.CharacteristicsCluster 1 (N = 253)Cluster 2 (N = 257)Total (N = 510) p Age 3.00E−04Mean ± SD63.67 ± 9.9166.89 ± 9.9565.28 ± 10.05Median [min–max]64.00 [40.00, 88.00]68.00 [33.00, 87.00]66.00 [33.00, 88.00] Sex 4.00E−04Female116 (22.75%)159 (31.18%)275 (53.92%)Male137 (26.86%)98 (19.22%)235 (46.08%) T_stage 2.30E−03T164 (12.62%)103 (20.32%)167 (32.94%)T2152 (29.98%)124 (24.46%)276 (54.44%)T323 (4.54%)22 (4.34%)45 (8.88%)T413 (2.56%)6 (1.18%)19 (3.75%) N_stage 0.08N0152 (30.52%)175 (35.14%)327 (65.66%)N154 (10.84%)41 (8.23%)95 (19.08%)N242 (8.43%)32 (6.43%)74 (14.86%)N32 (0.40%)0 (0.0e+0%)2 (0.40%) M_stage 0.28M0174 (47.28%)169 (45.92%)343 (93.21%)M116 (4.35%)9 (2.45%)25 (6.79%) Tumor_stage 0.01Stage I118 (23.46%)155 (30.82%)273 (54.27%)Stage II65 (12.92%)55 (10.93%)120 (23.86%)Stage III51 (10.14%)33 (6.56%)84 (16.70%)Stage IV16 (3.18%)10 (1.99%)26 (5.17%) Prior cancer diagnosis occurence 0.94No208 (40.78%)213 (41.76%)421 (82.55%)Yes45 (8.82%)44 (8.63%)89 (17.45%) Location lung parenchyma 1Central lung33 (17.65%)27 (14.44%)60 (32.09%)Peripheral lung69 (36.90%)58 (31.02%)127 (67.91%) Patient primary tumor site 0.4L‐Lower31 (6.26%)45 (9.09%)76 (15.35%)L‐Upper61 (12.32%)61 (12.32%)122 (24.65%)R‐Lower44 (8.89%)50 (10.10%)94 (18.99%)R‐Middle11 (2.22%)10 (2.02%)21 (4.24%)R‐Upper98 (19.80%)84 (16.97%)182 (36.77%) Tobacco_smoking_history 3.00E−05124 (4.84%)50 (10.08%)74 (14.92%)276 (15.32%)43 (8.67%)119 (23.99%)354 (10.89%)80 (16.13%)134 (27.02%)491 (18.35%)74 (14.92%)165 (33.27%)53 (0.60%)1 (0.20%)4 (0.81%) Adjuvant postoperative targeted therapy 0.05No57 (37.25%)60 (39.22%)117 (76.47%)Yes25 (16.34%)11 (7.19%)36 (23.53%) Primary therapy outcome success type 1.40E−03CR/PR61 (41.22%)68 (45.95%)129 (87.16%)PD/SD17 (11.49%)2 (1.35%)19 (12.84%) Fraction genome altered 8.40E−25Mean ± SD0.35 ± 0.180.18 ± 0.160.27 ± 0.19Median [min–max]0.35 [3.0e−4, 0.78]0.14 [0.0e+0, 0.80]0.24 [0.0e+0, 0.80] TMB (nonsynonymous) 1.90E−04Mean ± SD9.54 ± 8.736.76 ± 7.308.00 ± 8.07Median [min–max]6.47 [1.40, 44.77]4.13 [0.43, 44.03]5.33 [0.43, 44.77] Note: Lifelong Non‐smoker (less than 100 cigarettes smoked in Lifetime) = 1: Never smoked; Current smoker (including daily smokers and non‐daily smokers or occasional smokers) = 2: Current smoker (including regular smokers and occasional smokers); Current reformed smoker for > 15 years (greater than 15 years) = 3: quit smoking > 15 years; Current reformed smoker for ≤ 15 years (less than or equal to 15 years) = 4: quit smoking < 15 years; Current reformed smoker, duration not specified = 5: Quit smoking, the time of quitting smoking is unknown. Comparison of clinical information among subtypes. Note: Lifelong Non‐smoker (less than 100 cigarettes smoked in Lifetime) = 1: Never smoked; Current smoker (including daily smokers and non‐daily smokers or occasional smokers) = 2: Current smoker (including regular smokers and occasional smokers); Current reformed smoker for > 15 years (greater than 15 years) = 3: quit smoking > 15 years; Current reformed smoker for ≤ 15 years (less than or equal to 15 years) = 4: quit smoking < 15 years; Current reformed smoker, duration not specified = 5: Quit smoking, the time of quitting smoking is unknown. Immune Microenvironment To uncover whether inflammatory cell death‐based subtypes correspond to distinct tumor immune microenvironment landscapes, we systematically evaluated immune cell infiltration, HLA expression, immune checkpoint abundance and hallmark pathway enrichment between Cluster 1 and Cluster 2. As depicted in Figure 3A, the immune cell infiltration profile reveals marked disparities across 11 cell types. The MCPCounter algorithm analysis revealed substantial disparities in eight immune cell populations between the two groups (Figure 3B). Cluster 2 samples exhibited substantially higher immune, stromal, and estimated scores according to the ESTIMATE algorithm than Cluster 1 samples (Figure 3C). The comparison of HLA family gene expression levels between Clusters 1 and 2 is shown in Figure 3D, and we observed that 19 HLA family genes showed higher expression in Cluster 2. Meanwhile, 15 upregulated immune checkpoint genes were observed in Cluster 2 compared with those in Cluster 1 (Figure 3E). Enrichment analysis of the hallmark gene set showed that the DE genes between Clusters 1 and 2 were significantly enriched in 11 upregulated and 19 downregulated hallmark gene sets (Figure 3F). Specifically, the upregulated pathways are mainly associated with tumor proliferation and metabolic activity, including HALLMARK_DNA_REPAIR, HALLMARK_E2F_TARGETS, HALLMARK_G2M_CHECKPOINT, HALLMARK_MITOTIC_SPINDLE, HALLMARK_MTORC1_SIGNALING, HALLMARK_MYC_TARGETS_V1, HALLMARK_MYC_TARGETS_V2, HALLMARK_OXIDATIVE_PHOSPHORYLATION, HALLMARK_SPERMATOGENESIS, and HALLMARK_UNFOLDED_PROTEIN_RESPONSE. In contrast, the downregulated pathways are predominantly linked to immune and inflammatory responses, such as HALLMARK_ALLOGRAFT_REJECTION, HALLMARK_COMPLEMENT, HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION, HALLMARK_IL2_STAT5_SIGNALING, HALLMARK_IL6_JAK_STAT3_SIGNALING, HALLMARK_INFLAMMATORY_RESPONSE, HALLMARK_INTERFERON_ALPHA_RESPONSE, HALLMARK_INTERFERON_GAMMA_RESPONSE, HALLMARK_KRAS_SIGNALING_UP, and HALLMARK_TNFA_SIGNALING_VIA_NFKB. This indicates that the two molecular subtypes exhibit drastically distinct pathway activation signatures, which further explains their discrepancies in immune microenvironment and clinical prognosis. Immune microenvironment assessment between the two subgroups (Cluster1 n = 253, Cluster2 n = 257). (A) Box diagram of immune cell distribution estimated based on Cibersort algorithm; vs. Cluster 2, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; Wilcoxon rank‐sum test. (B) Box diagram of immune cell distribution estimated based on MCPCounter algorithm; vs. Cluster 2, *p < 0.05, ***p < 0.001, and ****p < 0.0001; Wilcoxon rank‐sum test. (C) Violin chart of the distribution of immune score, normal score and microenvironment score in the two subtypes; Wilcoxon rank‐sum test. (D) Box diagram of HLA family genes; data presented as mean ± SD; two‐tailed independent Student's t‐test. (E) Box diagram of immune checkpoint genes; data presented as mean ± SD; two‐tailed independent Student's t‐test. (F) GSEA enrichment results of hallmark gene set; left‐side represents upregulated inflammatory cell death genes and right‐side represents downregulated inflammatory cell death genes. GSEA statistical threshold: adjusted p < 0.05. Optimal Prognosis‐Associated Inflammatory Cell Death Genes To filter independent inflammatory cell death regulators with prognostic value and construct a robust predictive signature for LUAD overall survival, we sequentially applied univariate Cox regression and LASSO penalized regression. The univariate Cox regression revealed a strong association between eight DE inflammatory cell death genes (YWHAG, FADD, IL1A, CYCS, TFDP1, BAK1, HMGB2, BMF) and patient prognosis (Figure 4A). Further, the LASSO Cox compression algorithm verified seven optimized characteristic gene combinations and prognostic regression coefficients, including BAK1, BMF, CYCS, FADD, IL1A, TFDP1, and YWHAG (Figure 4B). The RiskScore model was built on the UCSC‐Xena training set (Figure 4C) and externally validated with the GSE72094 verification set (Figure 4D). We observed that samples with a low RiskScore had better OS, and OS time was positively associated with the RiskScore. For the training set, the ROC curves for 1‐, 3‐, and 5‐year survival rates were 0.703, 0.68, and 0.73, respectively. Meanwhile, the GSE72094 verification set yielded ROC values of 0.617, 0.624, and 0.71 for these survival periods. In addition, the risk model significantly discriminated survival outcomes between patients in the high‐ and low‐risk groups in the second independent external validation cohort GSE31210 (log‐rank p < 0.05), with 1‐, 3‐, and 5‐year AUC values of 0.693, 0.742, and 0.750, respectively (Figure S2). Collectively, these multiple external validation results fully demonstrate that this seven‐gene inflammatory cell death risk model exhibits stable predictive performance across distinct LUAD populations. Optimal prognosis‐associated inflammatory cell death genes. (A) Single factor Cox regression results of forest map of prognostication‐related inflammatory cell death genes; n = 497 patients with complete survival data. (B) LASSO regression process parameter diagram; n = 497. (C) Kaplan–Meier (KM) curve, RiskCcore distribution, and receiver operating characteristic (ROC) curve of high‐ and low‐risk group in TCGA. (D) KM curve, RiskScore distribution, and ROC curve of high‐ and low‐risk groups in GSE72094. KM survival comparison: two‐sided Log‐rank test. RiskScore Was Related With Clinical Characteristics of Patients To clarify the clinical relevance of our inflammatory cell death‐derived RiskScore, we analyzed its distribution across standard pathological and demographic variables. The correlation between RiskScore and multiple clinical parameters, notably N stage, was depicted using a box chart (Figure 5A), tumor stage (Figure 5B), T stage (Figure 5C), and smoking history (Figure 5D). RiskScore exhibited significant variations across distinct N stages, tumor stages, T stages, and smoking history categories. Furthermore, RiskScore was positively related to the severity of the disease and the proportion of gene mutations (Figure 5E), whereas RiskScore was significantly negatively correlated with age (Figure 5F). Higher inflammatory cell death risk scores correlate with advanced tumor staging, heavier genomic instability and younger age in LUAD patients. Distribution box chart of RiskScore under different clinical factors and correlation scatter chart between RiskScore and continuous clinical variables. Total sample n = 497 TCGA‐LUAD patients with complete clinical and survival data. (A) N stage; (B) tumor stage; (C) T stage; (D) tobacco smoking history; For (A–D) data are presented as median (IQR). Comparisons among multiple groups were performed using two‐sided Kruskal‐Wallis test followed by Dunn's post hoc test; comparisons between two groups used two‐tailed Wilcoxon test. (E) Correlation scatter chart between RiskScore and fraction genome altered; Spearman correlation analysis. (F) Correlation scatter chart between RiskScore and age; Spearman correlation analysis. Independent Prognostic Factors To verify whether the inflammatory cell death RiskScore serves as an independent survival predictor after adjusting for conventional clinical parameters, we conducted sequential univariate and multivariate Cox regression analyses. Significant associations with overall survival time were found for RiskScore, T stage, N stage, and M stage in the univariate analysis (Figure 6A). Multivariate regression analysis confirmed that RiskScore, T stage, and N stage were independent prognostic factors for LUAD (Figure 6B). To verify the accuracy of the prognostic model, a nomogram map (Figure 6C), accuracy correction curve (Figure 6D), and ROC curve (Figure 6E) were constructed, and the RiskScore model demonstrated superior predictive capability, achieving AUC values of 0.701 for 3‐year survival, 0.692 for 5‐year survival, and 0.687 for 1‐year survival. The seven‐gene inflammatory cell death signature adds independent prognostic value beyond traditional TNM staging for LUAD survival prediction. Independent prognostic factors exploration. Sample size n = 497 TCGA‐LUAD patients with complete clinicopathological and survival data. (A) Univariate regression of clinical factors; (B) Multivariate regression of clinical factors; (C) Nomogram map integrating independent prognostic factors RiskScore, T stage, N stage to predict 1‐, 3‐, 5‐year overall survival probability for individual LUAD patients; (D) Normgram calibration curve and receiver operating characteristic (ROC) curve. (E) Receiver operating characteristic (ROC) curve of the nomogram. Genome Change, Immune Correlation, and Drug Sensitivity To characterize genomic heterogeneity, immune regulatory patterns and therapeutic susceptibility associated with the inflammatory cell death risk stratification, we compared somatic mutation profiles, gene‐immune cell correlations and compound IC50 values between high‐ and low‐risk cohorts. The mutation waterfall plots for the top 20 genes were generated for both the low‐risk cohort (Figure 7A) and high‐risk cohort (Figure 7B) were constructed, and different high‐frequency mutation genes were observed between the two groups. The scatter of the correlation between TMB value and RiskScore of each sample is shown in Figure 7C, and we found that TMB was positively related to RiskScore. The relationship between seven optimal combinations of DE inflammatory cell death genes and 20 immune cells is shown in Figure 7D. We found that all genes were related to most immune cells. Among them, IL1A was positively associated with 11 immune cells while showing inverse relationships with four others. Furthermore, significant variations in drug response (IC50) were identified for 85 compounds, with docetaxel, parthenolide, and roscovitine among them, when contrasting the two risk groups. Overall, these findings collectively indicate that the inflammatory cell death‐based risk stratification not only distinguishes distinct genomic alteration landscapes and immune‐cell interaction patterns but also identifies differential drug sensitivities, suggesting its potential utility in guiding personalized therapeutic strategies and prognosis prediction. Genome change, immune correlation, and drug sensitivity in high‐ and low‐risk groups. (A) Top20 gene waterfall chart of mutation frequency in low‐risk group (n = 248); (B) Top20 gene waterfall chart of mutation frequency in high‐risk group (n = 249); (C) TMB distribution violin chart of high‐ and low‐risk groups; Spearman correlation analysis and Wilcoxon rank‐sum test. (D) Correlation heat map of seven model genes and differential immune cells and two stromal cells between the two subtypes; Spearman correlation analysis. Immunotherapy Sensitivity and Enriched Metabolism Pathway To investigate whether inflammatory cell death‐based risk stratification is associated with immunotherapy response and aberrant metabolic pathways, we further compared multiple predictive biomarkers for immunotherapy and the differences in KEGG pathway enrichment between the high‐risk and low‐risk groups. The high‐risk cohort exhibited substantially elevated TIDE scores compared to the low‐risk cohort, indicating that patients with lower risk profiles may derive greater therapeutic benefit from immune checkpoint blockade (Figure 8A). Samples categorized as high‐risk demonstrated a pronounced reduction in IPS scores relative to the low‐risk cohort (Figure 8B), implying enhanced immunogenic potential in the latter. The CYT score remained essentially equivalent between the high‐ and low‐risk cohorts, with no detectable difference (Figure 8C). Genes in the high‐ and low‐risk cohorts were differentially enriched in 14 KEGG pathways, including fatty acid, taurine and hypotaurine, fructose and mannose, and galactose metabolism (Figure 8D). In the RiskScore distribution analysis, 54% of Cluster 1 samples were assigned to the high‐risk cohort, in contrast to 46% of Cluster 2 samples (Figure 8E), underscoring the differential risk allocation. Our analysis revealed that Cluster 1 samples demonstrated a substantially greater RiskScore than those in Cluster 2 (Figure 8F). In addition, we evaluated the relationship between molecular subtypes and the prognostic model. As shown in Figure S3, the expression levels of all seven model genes (BAK1, BMF, CYCS, FADD, IL1A, TFDP1, and YWHAG) differed significantly between the two subtypes, further confirming that the prognostic model effectively reflects the inflammatory cell death‐related heterogeneity captured by consensus clustering. Immunotherapy sensitivity and enriched metabolism pathway in high‐ and low‐risk groups. (A) Box diagram of TIDE score; (B) Box diagram of CYT score; (C) Box diagram of IPS score; For (A)–(C), data are presented as median (IQR). Comparisons between high‐ (n = 249) and low‐risk (n = 248) groups were performed using the two‐tailed Wilcoxon rank‐sum test. (D) Distribution heat map of enrichment score of differential metabolic pathway in each sample; limma moderated t‐test combined with GSVA. (E) Box diagram of the distribution of the two subtypes in the high‐ and low‐risk groups; Chi‐square test was used to compare subtype proportions. (F) Box diagram of RiskScore distribution in the two subtypes; two‐tailed Wilcoxon test. Expression Validation of Inflammatory Cell Death‐Related Genes in LUAD Cell Lines To verify the differential expression pattern of the seven inflammatory cell death signature genes observed in clinical LUAD tissues at the cellular level, we detected their mRNA expression levels in three human LUAD cell lines (A549, H1299, PC‐9) and normal human bronchial epithelial cell line BEAS‐2B via RT‐qPCR. The expression of seven inflammatory cell death regulatory factors (BAK1, BMF, CYCS, FADD, IL1A, TFDP1, and YWHAG) was detected by RT‐qPCR in A549, H1299, PC‐9, and BEAS‐2B cell lines. Compared to BEAS‐2B, the mRNA expression levels of BAK1, BMF, CYCS, FADD, TFDP1, and YWHAG were significantly upregulated in LUAD cell lines, while IL1A expression was significantly downregulated (all, p < 0.05, Figure 9). Consistent with the transcriptomic data mined from clinical LUAD cohorts, in vitro cellular expression assays recapitulated the dysregulated expression landscape of the seven inflammatory cell death prognostic genes, which further validated the reliability of our seven‐gene signature. Among these, the upregulation of these genes was most pronounced in the A549 cell line. Among these genes, YWHAG exhibited the highest expression level; however, it has been extensively studied in LUAD. In contrast, the apoptotic regulatory mechanisms of TFDP1 in LUAD have been less investigated, making it more amenable to uncovering novel mechanisms. Therefore, we selected the A549 cell line and TFDP1 for subsequent functional experiments. Overall, the high‐risk group exhibited a tendency toward immunotherapy resistance and metabolic reprogramming signatures, suggesting that this risk score may modulate the tumor immune microenvironment by regulating multiple metabolic pathways, thereby providing a potential foundation for individualized immunotherapy strategies based on inflammatory cell death‐related risk stratification. Expression of seven inflammatory cell death regulatory factors (BAK1, BMF, CYCS, FADD, IL1A, TFDP1, and YWHAG) in LUAD cell lines (A549, H1299, PC‐9) and normal lung epithelial cells (BEAS‐2B) as detected by RT‐qPCR. Each experiment was independently repeated three times (n = 3 biological replicates per cell line). Data are presented as mean ± SD. Statistical significance was determined by one‐way ANOVA followed by Tukey's post hoc test for multiple comparisons (two‐tailed). *p < 0.05; **p < 0.01; ***p < 0.001. Effect of TFDP1 Gene Knockdown on the Function of LUAD Cells To assess the functional contribution of TFDP1 to LUAD cell malignant phenotypes, we transfected A549 cells with siRNA targeting TFDP1 (si‐TFDP1) and verified knockdown efficiency at both mRNA and protein levels. The RT‐qPCR analysis revealed a dramatic decrease in TFDP1 mRNA expression in the si‐TFDP1 group compared to the control (p < 0.001, Figure 10A). Further confirmation of the successful TFDP1 knockdown was provided by Western Blot analysis, which showed a significant downregulation of TFDP1 protein in the si‐TFDP1 group (p < 0.001, Figure 10B). Notably, the CCK‐8 assay demonstrated that TFDP1 knockdown effectively impaired the proliferative capacity of A549 cells (p < 0.01, Figure 10C). The Transwell assay revealed that TFDP1 knockdown obviously reduced the migratory and invasive abilities of A549 cells (p < 0.001, Figure 10D,E). The apoptosis of A549 cells was detected by Annexin V/PI flow cytometry. The results showed that the total apoptosis rate was significantly higher in the si‐TFDP1 group compared to the si‐NC group (p < 0.001, Figure 10F). Collectively, endogenous TFDP1 overexpression enhances the core malignant phenotypes of LUAD cells (proliferation, migration and invasion) and suppresses apoptosis, further validating its regulatory role in inflammatory cell death. TFDP1 knockdown inhibits A549 cell proliferation, migration, and invasion while promoting apoptosis. (A, B‌) RT‐qPCR (A) and Western Blot (B) validation of TFDP1 knockdown efficiency. (C) CCK‐8 assay measuring absorbance values (450 nm) over time. (D, E) TFDP1 knockdown suppresses A549 cell migration (D) and invasion (E); the scale bar in all micrographs represents 100 μm (original magnification: 100×, achieved with a 10× objective lens and a 10× eyepiece lens). (F) Flow cytometry analysis of A549 cell apoptosis. All experiments were performed with three independent biological replicates (n = 3 per group). Data are presented as mean ± SD. Comparisons between si‐NC and si‐TFDP1 groups were performed using two‐tailed Student's t‐test. ‌**p < 0.01; ***‌p < 0.001. Discussion LUAD, the most aggressive and fatal type of tumor, stands as the predominant contributor to cancer‐related mortality in China. In our research, we identified 15 upregulated and nine downregulated inflammatory cell death regulators in LUAD. The RiskScore model based on seven inflammatory cell death regulators (BAK1, BMF, CYCS, FADD, IL1A, TFDP1, and YWHAG) showed good performance in LUAD prognosis prediction. Docetaxel, parthenolide, and rocovitine are potential therapeutic drugs that target the prognostic signature of inflammatory cell death. The progression of LUAD has been found to critically depend on inflammatory cell death regulators, as evidenced by a surge of recent studies examining their roles across multiple cancer types. Wang et al. identified 14 DE PANoptosis regulators by comparing unpaired and paired LUAD samples in GSE100720 [6]. Liu et al. identified 12 downregulated and 15 upregulated PANoptosis genes. Among these, 12 genes, including ITGA6, BAK1, and FADD, were identified as independent prognostic indicators for LUAD [28]. Wang et al. identified a FADD‐based PANoptosis signature as a valuable prognostic biomarker for LUAD [6]. BAK1 is a key effector of mitochondrial apoptosis [29]. Previous studies have confirmed that this gene can regulate cellular functions in NSCLC cells [30]. In line with prior findings, BAK1 and FADD emerged as prognostic indicators for LUAD. Furthermore, the other five genes, BMF, CYCS, IL1A, TFDP1, and YWHAG, were valuable combination prognostic markers. IL1A, as a molecule regulating tumor angiogenesis, metastasis, and growth, is significantly more abundant and has been verified as a diagnostic biomarker for NSCLC [31]. YWHAG belongs to a highly conserved protein family [12], and miR‐509‐5p can suppress NSCLC progression by targeting YWHAG, suggesting that the miR‐509‐5p/YWHAG axis may be a potential target for NSCLC diagnosis [32]. Although the roles of BMF and TFDP1 in LUAD have not yet been explored, BMF's role in promoting cancer cell survival [33] and TFDP1's role in the cell cycle pathway [34] prompted us to explore their roles in LUAD diagnosis further. Growing research has established that the inflammatory microenvironment, including its role in tumorigenesis and cancer progression, is a hallmark of cancer [35, 36]. Previous ROC analysis revealed that the sensitivity of the 1‐, 3‐, and 5‐year immune factor signatures was 0.715, 0.719, and 0.699, respectively [37]. Similarly, the seven‐inflammatory cell death‐regulator‐based RiskScore model demonstrated superior predictive capability, achieving AUC values of 0.701 for 3‐year survival, 0.692 for 5‐year survival, and 0.687 for 1‐year survival. Existing evidence indicates that in female LUAD cases, survival outcomes are independently influenced by tumor stage (including T, M, and N stages) and risk score [28]. Further evidence showed that changes in gene expression in LUAD, combined with basic clinical covariates, could improve OS prediction [38]. Docetaxel, parthenolide, and roscovitine were potential therapeutic drugs targeting the inflammatory cell death prognostic signature, suggesting that LUAD with a higher RiskScore may benefit more from these small‐molecule drugs. Roscovitine is accepted as a biological tool for regulating the cell cycle and for cancer research [39]. Parthenolide was the first small molecule to show selectivity against cancer stem cells [35]. Docetaxel initiates apoptosis and cell death by inactivating Bcl‐2 [36]. Although the antitumor activity of these drugs has been confirmed, their application in LUAD requires further validation. Although several PANoptosis‐related prognostic models have been reported for LUAD and other malignancies [40, 41, 42], the present study possesses multiple novel merits. First, to our knowledge, this work is the first to establish a prognostic model for LUAD based on a specific seven‐gene signature consisting of BAK1, BMF, CYCS, FADD, IL1A, TFDP1, and YWHAG. Notably, BMF and TFDP1 have not been documented in prior LUAD prognostic models constructed around inflammatory cell death. Second, distinct from previous studies limited to single‐gene analyses, we further investigated the clinical correlations between the RiskScore model and tumor mutational burden, immunotherapy responsiveness (TIDE/IPS), as well as fourteen KEGG metabolic pathways, offering a multi‐dimensional perspective on inflammatory cell death in LUAD. Most importantly, beyond bioinformatic modeling, we performed expression validation and functional assays in LUAD cell lines. Experimental results verified that TFDP1 knockdown suppresses the proliferation, migration, and invasion of LUAD cells while facilitating cellular apoptosis, thereby providing experimental evidence that TFDP1 acts as a regulatory mediator of inflammatory cell death during LUAD progression. Nevertheless, several limitations of the present study should be acknowledged. First, all transcriptomic and clinical data were retrieved from public databases, and retrospective public datasets inherently carry selection bias. Second, all in vitro validation experiments were performed solely using the A549 cell line; xenograft tumor models are required in future investigations to further validate the anti‐tumor effects induced by TFDP1 depletion. Third, protein expression levels of the seven signature genes were not detected in human lung adenocarcinoma tissues in this study, which prevents us from verifying the correlation between the risk score and the immune microenvironment of primary tumors at the clinical tissue level. In follow‐up work, we will systematically evaluate the prognostic stratification performance of this inflammatory cell death risk signature and elucidate its underlying regulatory mechanisms via multi‐center cohort validation, in vivo animal model experiments, and clinical tissue specimen analysis. This study identified a prognostic signature composed of seven inflammatory cell death regulators (BAK1, BMF, CYCS, FADD, IL1A, TFDP1, YWHAG) and constructed a well‐performing RiskScore model for LUAD prognosis prediction. Subsequent in vitro functional experiments confirmed that the key gene TFDP1 plays a protumorigenic role in LUAD, as its knockdown suppressed cellular growth, motility, and invasive capacity while triggering apoptosis. Our research not only elucidates the critical role of inflammatory cell death in LUAD prognosis and the tumor immune microenvironment but also experimentally validates that molecules such as TFDP1 may serve as potential therapeutic targets, providing new insights for the development of LUAD immunotherapy strategies. Author Contributions Yalun Yang: conceptualization, data curation, formal analysis, investigation, methodology, project administration, validation, visualization, writing – original draft, writing – review and editing. Di Liu: conceptualization, data curation, formal analysis, investigation, methodology, validation, visualization, writing – original draft, writing – review and editing. Shengwei Ma: conceptualization, project administration, resources, supervision, writing – review and editing. Funding The authors have nothing to report. Ethics Statement The transcriptomic data and clinical information used in this study were obtained from public databases (UCSC Xena, GEO, and cBioPortal), which have been approved by relevant ethical committees and made publicly available for research purposes. Therefore, ethical approval and informed consent were waived for this study. For the in vitro experiments involving A549 cells, all procedures were performed in accordance with the guidelines of the Ethics Committee of Jingzhou Central Hospital (Jingzhou, China) and complied with the Declaration of Helsinki. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Validation of inflammatory cell death‐related molecular subtypes in the independent external cohort GSE72094. GSE72094 validation cohort sample size n = 398 LUAD samples. (A) Consensus clustering matrix, CDF curves, and the delta area plot for the GSE72094 cohort, confirming the optimal number of clusters as k = 2. (B) Kaplan–Meier survival curves for the two subtypes in the GSE72094 cohort, together with a heatmap of 24 differentially expressed inflammatory cell death‐related genes and the accompanying distribution of clinical characteristics. Figure S2: KM curve, RiskScore distribution, and ROC curve of high‐ and low‐risk groups in GSE31210. n = 226. Patients were stratified by the median RiskScore derived from the TCGA training set. Survival was compared by two‐sided Log‐rank test. Time‐dependent ROC curves for 1‐, 3‐, and 5‐year OS with AUC values are shown. Figure S3: Boxplots showing the expression differences of the seven prognostic model genes (BAK1, BMF, CYCS, FADD, IL1A, TFDP1, and YWHAG) between Cluster 1 and Cluster 2. Data are presented as median (IQR). Comparisons were performed using two‐tailed Wilcoxon rank‐sum test.